These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 3411695)

  • 1. Tumor-specific immunotherapy of murine bladder cancer with butanol-extracted antigens and ethylchlorformate polymerized tumor protein.
    Rochester MG; Sarosdy MF; Pickett SH; Stogdill BJ; Lamm DL
    J Urol; 1988 Sep; 140(3):647-50. PubMed ID: 3411695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ethylchlorformate polymerized tumor protein immunotherapy of the murine bladder tumor.
    Mori K; Ikemoto S; Nishio S; Maekawa M
    Cancer; 1989 Feb; 63(4):667-70. PubMed ID: 2914272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long term protection in bladder cancer following intralesional immunotherapy.
    Reichert DF; Lamm DL
    J Urol; 1984 Sep; 132(3):570-3. PubMed ID: 6381762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
    Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
    Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunological protection induced by bacillus Calmette-Guérin treatment in a murine bladder tumor model.
    Iwasaki A; Kawai K; Hayashi H; Ikeda N; Toida I; Ohtani M; Akaza H
    Int J Urol; 2002 Apr; 9(4):219-24. PubMed ID: 12010317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapeutic strategies for high-risk bladder cancer.
    Sharma P; Old LJ; Allison JP
    Semin Oncol; 2007 Apr; 34(2):165-72. PubMed ID: 17382800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy of murine transitional cell carcinoma.
    Lamm DL; Reichert DF; Harris SC; Lucio RM
    J Urol; 1982 Nov; 128(5):1104-8. PubMed ID: 6757465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy for bladder cancer using recombinant bacillus Calmette-Guerin DNA vaccines and interleukin-12 DNA vaccine.
    Lee CF; Chang SY; Hsieh DS; Yu DS
    J Urol; 2004 Mar; 171(3):1343-7. PubMed ID: 14767345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allium sativum (garlic) treatment for murine transitional cell carcinoma.
    Riggs DR; DeHaven JI; Lamm DL
    Cancer; 1997 May; 79(10):1987-94. PubMed ID: 9149027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential immunocytological evaluation of murine transitional cell carcinoma during intralesional bacillus Calmette-Guerin and interleukin-2 immunotherapy.
    Sosnowski JT; De Haven JI; Abraham FM; Riggs DR; Lamm DL
    J Urol; 1992 May; 147(5):1439-43. PubMed ID: 1569700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunotherapy of superficial bladder cancer].
    Schmitz-Dräger BJ; Schattka SO; Ebert T
    Urologe A; 1993 Sep; 32(5):374-81. PubMed ID: 8212422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced antitumor effect of Bacillus Calmette-Guérin in combination with fibrinogen on urinary bladder tumor.
    Mizutani Y; Nio Y; Fukumoto M; Yoshida O
    J Urol; 1994 May; 151(5):1420-6. PubMed ID: 8158799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Keyhole limpet hemocyanin immunotherapy of murine bladder cancer.
    Lamm DL; DeHaven JI; Riggs DR; Delgra C; Burrell R
    Urol Res; 1993 Jan; 21(1):33-7. PubMed ID: 8456536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of action of bacillus Calmette-Guérin in the treatment of superficial bladder cancer.
    Patard JJ; Chopin DK; Boccon-Gibod L
    World J Urol; 1993; 11(3):165-8. PubMed ID: 8401636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From the 19th to the 21st centuries: BCG in the treatment of superficial bladder cancer.
    Morales A
    Eur Urol; 1992; 21 Suppl 2():2-6. PubMed ID: 1396943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of antitumor response. Role of attachment and viability of bacillus Calmette-Guérin to bladder cancer cells.
    Akaza H; Iwasaki A; Ohtani M; Ikeda N; Niijima K; Toida I; Koiso K
    Cancer; 1993 Jul; 72(2):558-63. PubMed ID: 8319187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer.
    Lamm DL; DeHaven JI; Shriver J; Sarosdy MF
    J Urol; 1991 Apr; 145(4):738-40. PubMed ID: 2005691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined effect of interleukin 2 and bacillus Calmette-Guérin in the therapy of mice with transitional cell carcinoma.
    Ikemoto S; Kamizuru M; Wada S; Nishio S; Kishimoto T; Maekawa M
    Urol Int; 1991; 47(4):250-4. PubMed ID: 1781111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy of murine transitional cell carcinoma of the bladder using alpha and gamma interferon in combination with other forms of immunotherapy.
    Riggs DR; Tarry WF; DeHaven JI; Sosnowski J; Lamm DL
    J Urol; 1992 Jan; 147(1):212-4. PubMed ID: 1729535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.